Filing Flows › Sonoma Pharmaceuticals (SNOA) › Q4 FY26 › vs Q4 FY25
Sonoma Pharmaceuticals (SNOA) Q4 FY26 vs Q4 FY25 (year over year)
Sonoma Pharmaceuticals's revenue rose $1.8M (+48%) from $3.8M in Q4 FY25 to $5.6M in Q4 FY26.
Sonoma Pharmaceuticals, Q4 FY26: revenue $5.6M (+48% year over year), operating margin -6.3%, net loss $581K, operating cash flow −$519K. The chart draws each line against Q4 FY25, the increases inside each band.
Every line
| Line | Q4 FY26 | Q4 FY25 | Change | % |
|---|---|---|---|---|
| Revenue | $5.6M | $3.8M | $1.8M | +48% |
| Net loss | $581K | $776K | −$195K | -25% |
| Costs & expenses | $6.1M | $4.7M | $1.5M | +32% |
| Operating costs | $5.9M | $4.4M | $1.5M | +34% |
| Interest & other, net | $146K | −$128K | $274K | — |
| Income tax | $84K | $248K | −$164K | -66% |
| Cost of revenue | $3.4M | $2.2M | $1.2M | +52% |
| Research & development | $545K | $411K | $134K | +33% |
| SG&A | $2.0M | $1.8M | $214K | +12% |
| Operating cash sources | $687K | $216K | $471K | +218% |
| Depreciation & amortization | $33K | $31K | $2K | +6% |
| Share-based compensation | $135K | $90K | $45K | +50% |
| Cash used in operations | $519K | $95K | $424K | +446% |
| Net loss absorbed | $581K | $776K | −$195K | -25% |
| Working capital & other | $106K | −$560K | $666K | — |
Questions
How much did Sonoma Pharmaceuticals's revenue grow year over year in Q4 FY26?
Sonoma Pharmaceuticals's revenue rose $1.8M (+48%) from $3.8M in Q4 FY25 to $5.6M in Q4 FY26.